Skip to main content
PMC home page
BMC Complementary Medicine and Therapies logoLink to BMC Complementary Medicine and Therapies
. 2020 Jul 17;20:225. doi: 10.1186/s12906-020-02985-6

Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis

Ganpeng Yu 1,✉, Wang Xiang 2,3, Tianqing Zhang 4,5, Liuting Zeng 6, Kailin Yang 7, Jun Li 1,✉
PMCID: PMC7368679  PMID: 32680575

Abstract

Background

Osteoarthritis (OA) is the commonest form of inflammatory joint disease. Unfortunately, to date, there is no appropriate treatment for OA. Boswellia serrata was considered as a potent anti-inflammatory, anti-arthritic and analgesic agent that may be a drug for OA.

Methods

In this meta-analysis, data from randomized controlled trials were obtained to assess the effects of Boswellia or its extract versus placebo or western medicine in patients with OA. The primary outcomes included visual analogue score (VAS), WOMAC pain, WOMAC stiffness, WOMAC function and lequesne index.

Result

Seven trials involving 545 patients were included. Compared with the control group, Boswellia and its extract may relieve the pain [VAS: (WMD -8.33; 95% CI -11.19, − 5.46; P<0.00001); WOMAC pain: (WMD -14.22; 95% CI -22.34, − 6.09; P = 0. 0006)] and stiffness [WOMAC stiffness: (WMD -10.04; 95% CI -15.86, − 4.22; P = 0. 0007)], and improve the joint’s function [WOMAC function: (WMD -10.75; 95% CI -15.06, − 6.43; P<0. 00001); lequesne index: (WMD -2.27; 95% CI -3.08, − 1.45; P<0. 00001)].

Conclusion

Based on current evidence, Boswellia and its extract may be an effective and safe treatment option for patient with OA, and the recommended duration of treatment with Boswellia and its extract is at least 4 weeks.

Keywords: Boswellia, Boswellia extract, Osteoarthritis, Systematic review, Meta-analysis

Background

Osteoarthritis (OA) is an inflammatory joint disease that mainly damages articular cartilage. It is characterized by the degradation of articular cartilage and involving the entire joint tissue, which eventually leads to joint degeneration, fibrosis, fracture, defect and damage to the entire articular surface [1–3]. Epidemiological studies show that there are currently 355 million people with arthritis worldwide, and arthritis has become the world’s number one disabling disease. In China, as of 2015, there were 120 million people with arthritis in mainland China, with an incidence rate of about 13%, of which the number of people suffering from OA is the largest [4]. The management of patients with knee OA is mainly based on individualized and gradient treatment for the condition and severity of arthritis [5–7]. Among them, the drugs for OA pain are mainly non-steroidal anti-inflammatory drugs (NSAID) and specific (COX-2) cyclooxygenase II inhibitors [8]. However, these drugs may be expensive or cause stomach bleeding, and cannot repair cartilage and treat subchondral damage [8–10]. Therefore, due to the high incidence of NSAID-related adverse events, there is an urgent need for a safer and effective alternative to OA.

Boswellic acid is the active ingredient in Boswellia serrata; it has shown significant pharmacological activity in the treatment of inflammatory diseases such as rheumatoid arthritis, chronic bronchitis, asthma and chronic inflammatory bowel diseases (ulcerative colitis and Crohn’s disease) [11, 12]. Current research showed that 3-O-Acetyl-11-keto-beta-boswellic acid (AKBA) is the one boswellic acid with strong pharmacological activity; for example, AKBA has a powerful inhibitory effect on 5-lipoxygenase (5-LOX) [13, 14]. Clinical studies have shown that Boswellia serrata extract not only has anti-inflammatory and anti-arthritis properties, but also improves pain and physical function [15–18]; in vitro experiments also show that Boswellia serrata extract can inhibit the expression of inflammatory factors such as adhesion molecules [19–23]. With regard to the safety of Boswellia serrata, studies showed that Boswellia serrata extract (such as 5-Loxin and Aflapin) does not have toxic side effects at higher doses [23–25]. These indicate that the active compound of Boswellia extract (AKBA) is safe based on current evidence [23, 25].

As potential anti-inflammatory drugs for OA, the efficacy of Boswellia and Boswellia Extract have been reported in a lot of clinical trials [14–17, 24, 26]. Since 2003 [15], many trials have explored the feasibility of Boswellia and its extracts for the treatment of OA. In the meantime, the latest randomized controlled trials (RCTs) have assessed the benefits and adverse events of Boswellia and its extract for OA. To the best of our knowledge, this is the first systematic review and meta-analysis estimating the effectiveness and safety of Boswellia and its extracts for OA. Therefore, we hope that the results of this systematic review and meta-analysis will provide better evidence for the clinical application of Boswellia and its extract in the treatment of OA.

Why it is important to do the review

Boswellia and its extract have theoretical benefits for cultured cells in vitro and experimental animals [19, 21–23, 25, 27]; although several meta-analyses have widely analyzed the effect of herb or dietary supplements on OA [28, 29], to our knowledge, there is no systematic review and meta-analysis focused on assessing the efficacy of Boswellia and its extract on OA. For example, Liu et al. [28] conducted a systematic review about dietary supplements for patients with osteoarthritis; Of the studies it included, only three RCTs were about Boswellia and its extract. Meanwhile, its conclusions about Boswellia and its extract on OA failed to provide valuable reference information for clinical decision making. Another systematic review [29] only analyzed the RCTs before 2013. In 5 years, more RCTs about Boswellia and its extract on OA have been completed, which means that relevant conclusions need to be updated or confirmed. Therefore, this systematic review and meta-analysis focus on and summarizes available evidence from RCTs about the role of Boswellia and its extract in OA.

Materials and methods

Protocol

Systematic reviews and meta-analysis are carried out strictly in accordance with the protocol (CRD42018086785) and the PRISMA-guidelines (see Supplementary Materials) [30].

Search strategy and selection criteria

Web of Science, the Chinese Science and Technology Periodical Database (VIP), Wan Fang Database (Chinese Ministry of Science & Technology), EMBASE, Medline Complete, Chinese Biomedical Database (CBM), ClinicalTrials, the China National Knowledge Infrastructure Databases (CNKI), Pubmed, Cochrane Library (Until Issue 2, 2018) were searched with keywords “boswellic acid”, “Boswellia”, “Shallaki”, “Salai”, “aflapin”, “5-loxin” and “osteoarthritis”. The search period is from the establishment of the journal to January 2018.

Selection criteria

Participants

Human with specified diagnosis criteria of OA.

Intervention methods

Boswellia or its extract.

Comparison methods

Other treatments for OA, such as placebo or conventional medicine;

Outcomes

(1) Primary outcomes: visual analogue score (VAS), WOMAC pain, WOMAC stiffness, WOMAC function and lequesne index. (2) Secondary outcomes: WOMAC pain, WOMAC stiffness, WOMAC function at different points in time.

Study design

Randomized controlled trials (RCTs).

Information retrieval and data extraction method

Three researchers (Ganpeng Yu, Liuting Zeng and Kailin Yang) independently screened the literature based on protocol (CRD42018086785). The discrepancies between the three researchers would be resolved through discussion of all researchers. Literature retrieval is carried out according to the search strategy, the search strategy of Pubmed is shown in Table 1.

Table 1.

Search Strategy for Pubmed

Database Search Strategy
Pubmed

(boswellic acid OR Boswellia OR Boswellia sacra OR Boswellia serrata OR Boswellia carteri OR Boswellia carterii OR Shallaki OR Salai OR aflapin OR 5-loxin)

AND

(Osteoarthritis OR Osteoarthritides OR Osteoarthrosis OR Osteoarthroses OR Arthritis, Degenerative OR Arthritides, Degenerative OR Degenerative Arthritides OR Degenerative Arthritis OR Osteoarthrosis Deformans)

AND

(randomized controlled trial [pt] OR controlled clinical trial [pt] OR placebo [tiab] OR drug therapy [sh] OR trial [tiab] OR groups [tiab] OR clinical trials as topic [mesh: noexp] OR Clinical Trial OR random* [tiab] OR random allocation [mh] OR single-blind method [mh] OR double-blind method [mh] OR cross-over studies)

NOT

(animals [mh] NOT humans [mh])
Open in a new tab

After literature retrieval, three researchers (Ganpeng Yu, Liuting Zeng and Kailin Yang) extracted data from the included literature according to a pre-designed table (including author, year of publication, number of cases, inclusion and exclusion criteria of patients, duration of intervention, etc.). The discrepancies between the three researchers would be resolved through discussion of all researchers. The missing data in the literature would be obtained by contacting the author. If the author cannot be contacted, it would be estimated by the method provided by Cochrane Handbook 5.1.0 [31].

Literature quality evaluation methods

The Cochrane collaboration’s tool for assessing risk of bias provided by Cochrane Handbook 5.1.0 was used to evaluate the quality of the RCTs [32]. The evaluation content includes random sequence generation, allocation result concealment, blind method, incomplete result data, selective report and other biases. Four researchers (Ganpeng Yu, Wang Xiang, Tianqing Zhang, Liuting Zeng and Kailin Yang) independently assessed the quality of the literature. The discrepancies between the three researchers would be resolved through discussion of all researchers.

Statistical analysis

The RevMan5.3 software provided by the Cochrane collaboration network was used for system evaluation and meta-analysis. Enumeration data is represented by risk ratio (RR) and 95% confidence interval (CI), and measurement data is represented by mean deviation (MD) and CI. The heterogeneity between the results of the studies was tested by X2. If the heterogeneity of the study is low (P > 0.10, I2 < 50%), the fixed effect model is used for analysis; otherwise (P < 0.10, I2 > 50%), the source of heterogeneity is analyzed first and then subgroup analysis or random effect model is adopted.

Results

Results of the search

The total records identified through database searching and other sources were 513. Four hundred ninety-seven (497) were excluded based on the title and abstract and 16 for more detailed evaluation. After that, 7 studies were included [24, 26, 33–37], while 9 studies were excluded [15–18, 38–42] according to the inclusion criteria (Fig. 1). The 9 studies were Kimmatkar 2003 [15], Chopra 2004 [38], Shah 2010 [17], Chopra 2013 [39], Perera 2014 [16], Belcaro 2015 [40], Bolognesi 2016 [41], Gupta 2011 [18], Badria 2002 [42].

Fig. 1.

Fig. 1

Open in a new tab

Flow diagram of searching and article selection

Description of included trials

A total of 7 RCTs with 545 participants were included. Sengupta’s RCTs consist of 2 trial groups and 1 control group [24, 26]. According to the method of Cochrane Handbook 5.1.0, the control group was divided into two groups, matching the two trial groups (Sengupta 2008a and Sengupta 2008b; Sengupta 2010a and Sengupta 2010b) [31]. The characteristics of the RCTs were shown in Tables 2 and 3.

Table 2.

The characteristics of the included studies

Study Country Sample size Intervention Mean age (years)
Trial group Control group Trial group Control group Trial group Control group
Vishal 2011 [33] India 30 29 Aflapin 100 mg Placebo 100 mg 53.2 ± 6.5 55.3 ± 8.8
Sengupta 2008 [26] India 47 23 5-Loxin 100 mg or 250 mg Rice bran (placebo) 52.79 ± 8.47 52.43 ± 9.65
Sengupta 2010 [24] India 38 19 Aflapin 100 mg or 5-Loxin 100 mg Excipients (placebo) 100 mg 52.4 ± 8.87 52.4 ± 7.5
Haroyan 2018 [34] Armenia 67 68 Boswellic acid 150 mg + curcuminoids 350 mg Excipients (placebo) 500 mg 57.91 ± 9.02 56.04 ± 8.55
Karimifar 2017 [35] Iran 26 26 Boswellia + Elaeagnus Extraction Ibuprofen 52.0 ± 8.74 52.96 ± 8.57
Notarnicola 2016 [36] Italty 54 58 Boswellic acid 15 mg + Methylsulfonylmethane 10,000 mg Glucosamine sulfate 3000 mg 58.7 ± 12.5 59.5 ± 13.7
Notarnicola 2011 [37] Italty 30 30 Boswellic acid 7.5 mg + Methylsulfonylmethane 5000 mg Placebo 63.4 ± 8.2 60.2 ± 8.6
Open in a new tab

Table 3.

The characteristics of the included studies

Study Inclusion criteria Exclusion criteria Relevant outcomes Duration
Vishal 2011 [33]

1. Participants must understand risks and benefits of the protocol and able to give informed consent

2. Male and female subjects of 40–80 years of age

3. Females of child bearing potential must agree to use an approved form of birth control and have a negative pregnancy test result

4. Unilateral or bilateral OA of the knee for more than 3 months

5. Visual Analogue Scale (VAS) score during the most painful knee movement between 40 and 70 mm after 7 day withdrawal of usual medication

6. Lequesne’s Functional Index (LFI) score greater than 7 points after 7 days of withdrawal of usual medication

7. Ability to walk

8. Availability for the duration of the entire study period

1. History of underlying inflammatory arthropathy or severe rheumatoid arthritis (RA)

2. Hyperuricemia (greater than 440 umol/L) and/or past history of gout

3. Recent injury in the area affected by OA of the knee (past 4 months) and expectation of surgery in the next 4 months

4. Intra-articular corticosteroid injections within the last 3 months

5. Hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs), abnormal liver or kidney function tests, history of peptic ulceration and upper gastrointestinal (GI) haemorrhage, congestive heart failure, hypertension, hyperkalemia

6. Major abnormal findings on complete blood count, history of coagulopathies, haematological or neurological disorders

7. High alcohol intake (greater than 2 standard drinks per day)

8. Pregnant, breastfeeding or planning to become pregnant during the study

9. Use of concomitant prohibited medication other than ibuprofen

10. Obesity: body mass index (BMI) more than 30 kg/m^2

 VAS, WOMAC pain subscale, WOMAC stiffness subscale, WOMAC function subscale, Lequesne Index, adverse events 4 weeks
Sengupta 2008 [26] VAS, WOMAC pain subscale, WOMAC stiffness subscale, WOMAC function subscale, Lequesne Index, MMP-3, adverse events 12 weeks
Sengupta 2010 [24] VAS, WOMAC pain subscale, WOMAC stiffness subscale, WOMAC function subscale, Lequesne Index, adverse events 12 weeks
Haroyan 2018 [34] Patients with a diagnosis of degenerative hypertrophic osteoarthritis of the knee (M17, according to International Classification of Diseases (ICD-10) of bone joints, verified by radiography (Grade 1–3 by Kellgren-Lawrence radiographic grades).

1. subjects with inflammatory and any secondary arthritis

2. moderate and severe synovitis (grades 2 and 3) tear of meniscus

3. chronic diseases of the kidneys, liver, gastrointestinal, cardiovascular, endocrine and nervous systems

4. allergic anamnesis and drug intolerance

5. pregnant or nursing

6. history of substance abuse

7. subjects taking non-steroidal anti-inflammatory drugs and analgesics within 2 weeks prior to the study

8. subjects taking glucosamine sulfate, chondroitin sulfate, intra-articular hyaluronate, systemic or intra-articular glucocorticoids within 3 months prior to the study

 WOMAC pain subscale, WOMAC stiffness subscale, WOMAC function subscale, adverse events 12 weeks
Karimifar 2017 [35]

1. age of 40 to 80 years

2. knee osteoarthritis in at least one knee for at least 6 months based on ACR (American College of Rheumatology) diagnostic criteria

3. pain score > 4 based on VAS (visual analog scale)

4. LPFI (Lequesne Pain and Function Index) > 7

5. serum CRP (C-reactive protein) < 10 mg/dl and ESR (erythrocyte sedimentation rate) < 20 mg/dL, (6) grade 2 or 3 of KellgrenLawrence scale in knee radiography obtained within the last 6 months

7. free of liver, renal, or cardiac dysfunction

8. no use of intra-articular glucocorticoids or hyaluronic acid preparations within the last 3 months

9. no use of systemic glucocorticoids within the last 3 months

10. free of all other bone and joint disorders including rheumatoid arthritis and gout

11. free of peptic ulcer disease

12. no knee arthroscopic procedure within the last 3 months

13. not being pregnant or lactating (for women).

1. irregular use of capsules (less than 80% of total capsules)

2. no use of capsules for at least 3 days

 VAS, Lequesne Index, adverse events 4 weeks
Notarnicola 2016 [36]

1. a diagnosis of OA of the knee according to the criteria of the American College of Rheumatology

2. grade 3 Kellgren and Lawrence radiographic staging,16 in which the severity of the arthritis is assessed on a scale in the range of 0–4, hypothesizing a sequential evolution from the manifestation of osteophytes through a reduction in the width of the joint space, to subchondral sclerosis and finally the formation of cysts

3. frequent joint pain (several days a week) for at least 6 months before recruitment

4. pain in the knee, scored at least 4 cm on a 10 centimetric visual analogic scale (VAS) (from moderate to severe pain), where 0 means no pain and 10 is the worst pain possible

5. a score of > 2 on the Lequesne pain-function index (LI).18 The LI is an OA-specific validated questionnaire that poses a series of questions about pain in the knee (five questions on a scale from 0 to 2, where 0 indicates no pain and 2 intense pain), functional limitation (four questions, using the same scale), and maximum walking distance (one question, with a score from 0 to 6, where 0 indicates the ability to walk for an unlimited distance and 6, the inability to cover 100 m). The maximum worst final score is 24

1. previous surgery of the affected knee

2. disease processes such as rheumatoid arthritis, autoimmune diseases, systemic diseases, and tumors

3. severe obesity (BMI > 40 kg/m2)

4. meniscal or ligament injuries

5. allergy to shellfish

6. altered blood chemistry and kidney, liver, and metabolic (diabetes mellitus) function

7. intra-articular hyaluronic acid/cortisone infiltrations to the affected knee within 3 months before the start of the study

8. systemic cortisone treatment taken within 3 months before the start of the study;

9.supplements (glucosamine, chondroitin sulfate, bromeline, etc.) taken within 3 months before the start of the study (patients were also informed that they were not to be taken for the following 6 months)

 VAS, Lequesne Index 24 weeks
Notarnicola 2011 [37]

1. men and women > 45 and < 85 years of age;

2. a diagnosis of OA of the knee according to the criteria of the American College of Rheumatology

3. grade 3 Kellgren and Lawrence radiographic staging,13 in which the severity of the arthritis is assessed on a scale from 0 to 4, hypothesizing a sequential evolution from the manifestation of osteophytes through a reduction in the width of the joint space, to subchondral sclerosis and fnally the formation of cysts;

4. frequent joint pain (several days a week) for at least 6 months before recruitment;

5. pain in the knee, scored at least 2 cm on a 10 centimetric visual analogic scale (VAS), where 0 means no pain and 10 is the worst pain possible;

6. a score of > 2 on the Lequesne pain-function index (LI).14 The LI is a disease-specific validated questionnaire that poses a series of questions about pain in the knee (five questions on a scale from 0 to 2, where 0 indicates no pain and 2 intense pain), functional limitation (four questions, using the same scale) and maximum walking distance (one question, with a score from 0 to 6, where 0 indicates the ability to walk for an unlimited distance and 6, the inability to cover 100 m). The maximim worst fnal score was 24.

1. previous surgery of the affected knee;

2. disease processes such as rheumatoid arthritis, autoimmune diseases, systemic diseases, and tumors;

3. obesity (BMI > 30 kg/m2);

4. altered blood chemistry and kidney, liver, and metabolic (diabetes mellitus) function;

5. intra-articular hyaluronic acid/cortisone infiltrations to the affected knee within 3 months before the start of the study;

6. systemic cortisone treatment taken within 3 months before the start of the study;

7. supplements (glucosamine, chondroitin sulfate, bromeline, etc) taken within 3 months before the start of the study (patients were also informed that they were not to be taken for the following 6 months).

 VAS, Lequesne Index, adverse events 24 weeks
Open in a new tab

Risk of Bias in included studies

The summary and graph of risk of bias ware shown in Fig. 2.

Fig. 2.

Fig. 2

Open in a new tab

The risk of bias

Sequence generation

Among the 7 included RCTs, three studies [35–37] adopted unclear randomization procedures, we therefore rated it as having an unclear risk of bias. The other RCTs described their randomization procedures: Sengupta 2010 [24], Sengupta 2008 [26] and Vishal 2011 [33] utilized the computer-generated randomization scheme, while Haroyan 2018 [34] used the treatment randomization code to draw randomization. Thus, these RCTs were thought to have low risks of bias.

Allocation concealment

Sengupta 2010 [24], Sengupta 2008 [26], Vishal 2011 [33] and Haroyan 2018 [34] described that the appearance, smell and color of drugs preparations were similar and organoleptically indistinguishable, which is an acceptable method of allocation concealment. Hence, they were rated as having low risks of bias. Karimifar 2017 [35], Notarnicola 2016 [36] and Notarnicola 2011 [37] did not describe an acceptable method of allocation concealment; therefore, they were rated as having an unclear risk of bias.

Blinding

For blinding of participants and personnel, although all RCTs claim to use blinding, only Haroyan 2018 [34], Notarnicola 2016 [36] and Notarnicola 2011 [37] described the implementation process of blinding. Thus, we gave a low risk of bias for them. The other RCTs were rated as having an unclear risk of bias for they did not describe the blind implementation process.

For blinding of outcome assessment, the statisticians in Sengupta 2010 [24], Sengupta 2008 [26] and Vishal 2011 [33] wasn’t blinded, hence, they were rated as having a high risk of bias. Haroyan 2018 [34], Notarnicola 2016 [36] and Notarnicola 2011 [37] described the implementation process of blinding, hence, we gave a low risk of bias for them. Karimifar 2017 [35] were rated as having an unclear risk of bias for they did not describe the blind implementation process.

Incomplete outcome data

The missing outcome data of all RCTs balanced in numbers across intervention groups with similar reasons for missing data across groups. We gave them low risks of bias.

Selective reporting

One RCT (Vishal 2011 [33]) failed to provide all outcomes mentioned in its protocols, thus we thought its risk of bias was high. The other RCTs provided their protocols, and all of the study’s pre-specified outcomes that are of interest in the review had been reported in the pre-specified way; their risks of bias were low.

Other potential bias

In the RCTs of Sengupta 2010 [24], Sengupta 2008 [26] and Vishal 2011 [33], their protocols noted three primary outcome parameters, which means that when p = 0.05/3 = 0.017, the difference is significant. Strictly speaking, the statistics of this study were not carried out correctly. Hence, their risks of bias were high. Similarly, in Haroyan 2018 [34]‘s RCT, the difference is significant when p = 0.05 / 2 = 0.025. Its risk of bias was also high. Other sources of bias were not observed in other RCTs; therefore, the risks of other bias of them were low.

Primary outcomes

Visual analogue score

Six RCTs [24, 26, 33, 35–37] reported the changes of the visual analogue score (VAS) at the end of treatment. Due to the high heterogeneity (Tau2 = 10.85, I2 = 94%, P<0.00001), we used random effect model. In this index, it can be found that in improving VAS, Boswellia is better (WMD -8.33; 95% CI -11.19, − 5.46; P<0.00001). (Fig. 3).

Fig. 3.

Fig. 3

Open in a new tab

The changes of VAS

WOMAC

Four RCTs [24, 26-, 34–35] reported the changes of WOMAC pain. Due to the high heterogeneity (Tau2 = 94.69, I2 = 99%, P<0.00001), we used random effect model. According to the result, compared with the control group, Boswellia is better in improving WOMAC pain (WMD -14.22; 95% CI -22.34, − 6.09; P = 0. 0006). (Fig. 4).

Fig. 4.

Fig. 4

Open in a new tab

The changes of WOMAC pain

Four RCTs [24, 26, 33, 34] reported the changes of WOMAC stiffness. Due to the high heterogeneity (Tau2 = 44.40, I2 = 97%, P<0.00001), we used random effect model. According to the result, compared with the control group, Boswellia is better in improving WOMAC stiffness (WMD -10.04; 95% CI -15.86, − 4.22; P = 0. 0007). (Fig. 5).

Fig. 5.

Fig. 5

Open in a new tab

The changes of WOMAC stiffness

Four RCTs [24, 26, 33, 34] reported the changes of WOMAC function. Due to the high heterogeneity (Tau2 = 23.03, I2 = 93%, P<0.00001), we used random effect model. According to the result, compared with the control group, Boswellia is better in improving WOMAC function (WMD -10.75; 95% CI -15.06, − 6.43; P<0.00001). (Fig. 6).

Fig. 6.

Fig. 6

Open in a new tab

The changes of WOMAC function

Lequesne index

Six RCTs [24, 26, 33, 35–37] reported the changes of lequesne index. Due to the high heterogeneity (Tau2 = 0.55, I2 = 47%, P = 0.07), we used random effect model. According to the result, compared with the control group, Boswellia is better in improving Lequesne Index (WMD -2.27; 95% CI -3.08, − 1.45; P<0.00001). (Fig. 7).

Fig. 7.

Fig. 7

Open in a new tab

The changes of Lequesne Index

Secondary outcomes

Pain

Several RCTs reported Pain index (VAS and/or WOMAC pain) at week 4, 8, 12. The details of them were shown in Table 4 and Figure S1 ~ S6 (see Supplementary Materials).

Table 4.

the pain index at week 4, 8, 12

Secondary outcomes Overall effect Heterogeneity test Figure Reference
MD 95%CI P Tau2 I2 (%) P Statistical method Studies (N) Sample size (N)
VAS at 4 weeks −6.38 −10.20, −2.57 0.001 18.94 95% <0.00001 Random inverse variance 4 238 Fig S1 [24, 26, 33, 35]
VAS at 8 weeks −5.44 −8.8, −2.09 0.001 14.11 95 <0.00001 Random inverse variance 4 299 Fig S2 [24, 26, 36, 37]
VAS at 12 weeks −19.37 −23.90, − 14.85 <0.00001 – 43 0.15 Fixed inverse variance 2 127 Fig S3 [24, 26]
WOMAC pain at 4 weeks −6.91 − 11.08, −2.74 0.001 15.85 85 <0.0001 Random inverse variance 3 186 Fig S4 [24, 26, 33]
WOMAC pain at 8 weeks −11.05 −14.94, −7.17 <0.00001 10.57 79 0.003 Random inverse variance 2 127 Fig S5 [24, 26]
WOMAC pain at 12 weeks −12.37 −19.47, −5.26 0.0006 58.02 97 <0.00001 Random inverse variance 3 262 Fig S6 [24, 26, 34]
Open in a new tab

Stiffness

Several RCTs reported Stiffness index (WOMAC stiffness) at week 4, 8, 12. The details of them were shown in Table 5 and Figure S7 ~ S9 (see Supplementary Materials).

Table 5.

the stiffness index at week 4, 8, 12

Secondary outcomes Overall effect Heterogeneity test Figure Reference
MD 95%CI P Tau2 I2 (%) P Statistical method Studies (N) Sample size (N)
WOMAC stiffness at 4 weeks − 5.10 − 8.55, − 1.64 0.004 8.23 64 0.03 Random inverse variance 3 186 Fig S7 [24, 26, 33]
WOMAC stiffness at 8 weeks − 8.02 − 11.75, − 4.29 <0.0001 7.64 60 0.06 Random inverse variance 2 127 Fig S8 [24, 26]
WOMAC stiffness at 12 weeks − 10.97 − 19.30, − 2.63 0.010 82.6 99 <0.00001 Random inverse variance 3 262 Fig S9 [24, 26, 34]
Open in a new tab

Function

Several RCTs reported Function index (WOMAC function) at week 4, 8, 12. The details of them were shown in Table 6 and Figure S10 ~ S12 (see Supplementary Materials).

Table 6.

the function index at week 4, 8, 12

Secondary outcomes Overall effect Heterogeneity test Figure Reference
MD 95%CI P Tau2 I2 (%) P Statistical method Studies (N) Sample size (N)
WOMAC pain at 4 weeks − 7.18 − 10.56, − 3.80 <0.0001 9.23 81 0.0003 Random inverse variance 3 186 Fig S10 [24, 26, 33]
WOMAC pain at 8 weeks − 8.95 −13.56, − 4.35 0.0001 14.91 84 0.0004 Random inverse variance 2 127 Fig S11 [24, 26]
WOMAC pain at 12 weeks − 12.79 −18.41, − 7.43 <0.00001 22.56 94 <0.00001 Random inverse variance 3 262 Fig S12 [24, 26]
Open in a new tab

Adverse events

Five studies [24, 33–35, 37] reported AEs. Three of them were excluded because they reported no events in both arms. According to the results, there is also not strong evidence that which one is safer because there was no statistical difference (RR 0.63; 95% CI 0.22, 1.83; P = 0.39) (Fig. 8).

Fig. 8.

Fig. 8

Open in a new tab

Adverse events

Discussions

This systematic review and meta-analysis including 7 RCTs analyzes the effectiveness and safety of Boswellia and its extract for OA. Compared with the control group, Boswellia and its extract may relieve the pain (VAS and WOMAC pain) and stiffness (WOMAC stiffness), and improve the joint’s function (WOMAC function and lequesne index). In particular, since the doses of Boswellia and its extract reported in RCTs used for secondary outcomes analysis are 100–250 mg, based on the current evidence, pain, stiffness and joints’ function start to improve after 4 weeks of continuous Boswellia and its extract (at least 100–250 mg) intervention. While this finding seems promising, it should be interpreted with caution mainly due to the unclear risk of bias for selection bias (random sequence generation, allocation concealment) and attrition bias (incomplete outcome data), the high risk of bias for reporting bias (selective reporting), and the small number of participants.

Five studies [24, 33–35, 37] reported AEs. Three of them were excluded because they reported no events in both arms. According to the results, there is also not strong evidence that which one is safer because there was no statistical difference. However, safety studies conducted according to OECD guidelines and extensive acute and dose-dependent subchronic safety experiments on rats demonstrate that Boswellia and its extract does not exhibit toxic manifestations [23, 25], which means Boswellia and its extract might be a safety treatment option. But the absence of information on AEs does not mean that the intervention is safe [43]. Thus, although based on current evidences, we consider that Boswellia and its extract is a relatively safe treatment, we cannot assure it. Future clinical trials are required to report AEs with more explanations [44]. Thus, although based on current evidences, we consider that Boswellia and its extract is a relatively safe treatment, we cannot assure it. Future clinical trials are required to report AEs with more explanations [45].

Although there were several meta-analyses that have been widely analyzed the effect of herb or dietary supplements on OA [28, 29], as far as we know, this systematic review and meta-analysis is the first one that focused on evaluating the efficacy and safety of Boswellia and its extract for patients with OA. Compared with similar previous works [28, 29], we included more RCTs (including [33–36]) about Boswellia and its extract; thus, our conclusions were more accurate and reliable. In particular, compared with the work of Cameron et al. [29], we not only verified some outcomes (such as WOMAC) but also provide the recommended duration and dosage of Boswellia and its extract and so on. However, there are still some deficiencies in this study. For example, the risk of bias of some RCTs are high; the number of RCTs and cases included in this study is insufficient; the heterogeneity of some outcomes is high; these all affect the accuracy of the conclusions. The heterogeneity may be related to the discrepancies in the pharmacological effects of different Boswellia preparations. This may result from the different standardization of Boswellia and its extract manufacturing process, dosage, duration of treatment, units of laboratory tests and races of the selected patients or other places. Meanwhile, the recommended duration and dosage of treatment should also be interpreted with caution because the pain, stiffness and function index between week 1 and week 4 and the dosage of Boswellia and its extract outside 100–250 mg were not reported. Additionaly, since the quality of the RCTs is generally medium to low, all results should be interpreted more cautiously. Last but not least, further rigorously designed studies with high quality are needed to confirm the effectiveness and safety of Boswellia and its extract preparations for patients with OA.

Conclusion

This systematic review and meta-analysis showed that Boswellia and its extract may be a novel drug for patient with OA. Based on current evidence, the recommended duration and dosage of treatment with Boswellia and its extract is at least 100-250 mg 4 weeks. However, current RCTs have limitations, including the missing information of pain, stiffness and function index between week 1 and week 4 and small sample sizes. Meanwhile, since the quality of the RCTs is generally medium to low, we should formulate the conclusion more cautiously. More double-blind, large sample size RCTs of Boswellia and its extract for OA that reported pain, stiffness and function index before 4 weeks and the dosage of Boswellia and its extract outside 100–250 mg are needed in the future to confirm or modify the result of this work.

Supplementary information

Additional file 1. (61.9KB, tif)
Additional file 2. (61.6KB, tif)
Additional file 3. (55.9KB, tif)
Additional file 4. (59.4KB, tif)
Additional file 5. (56.9KB, tif)
Additional file 6. (60.6KB, tif)
Additional file 7. (59.2KB, tif)
Additional file 8. (56.9KB, tif)
Additional file 9. (60.1KB, tif)
Additional file 10. (59.5KB, tif)
Additional file 11. (57.6KB, tif)
Additional file 12. (57.3KB, tif)

Acknowledgments

Not applicable.

Abbreviations

OA

Osteoarthritis

NSAIDs

Non-steroidal anti-inflammatory drugs

MMP

Matrix metalloproteinase

RCT

Randomized controlled trials

AE

Adverse events

Authors’ contributions

GY, WX, LZ, KY are responsible for the study concept and design. GY, LZ, KY are responsible for the literature searching; GY, WX, TZ, LZ, KY and JL are responsible for data analysis and interpretation; GY, WX, TZ, LZ, KY drafted the paper; GY and JL supervised the study; all authors participated in the analysis and interpretation of data and approved the final paper. GY and WX should be considered joint first author. GY and JL should be considered co-corresponding authors.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials

All data generated or analyzed during this study are included in this published article and its supplementary information files.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Footnotes

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

Ganpeng Yu, Email: yuganpeng.guke@hotmail.com.

Jun Li, Email: lijun.guke@hotmail.com.

Supplementary information

Supplementary information accompanies this paper at 10.1186/s12906-020-02985-6.

References

  • 1.Felson DT. An update on the pathogenesis and epidemiology of osteoarthritis. Radiol Clin N Am. 2004;42:1–9. doi: 10.1016/S0033-8389(03)00161-1. [DOI] [PubMed] [Google Scholar]
  • 2.Felson DT, Lawrence RC, Dieppe PA, et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med. 2000;133:635–646. doi: 10.7326/0003-4819-133-8-200010170-00016. [DOI] [PubMed] [Google Scholar]
  • 3.Karen WB, Javaid K, Arden N, et al. Regular review: medical management of osteoarthritis. BMJ. 2000;321:936–940. doi: 10.1136/bmj.321.7266.936. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Beringer A, Miossec P. Systemic effects of IL-17 in inflammatory arthritis. Nat Rev Rheumatol. 2019;15(8):491–501. doi: 10.1038/s41584-019-0243-5. [DOI] [PubMed] [Google Scholar]
  • 5.Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum. 1995;38:1541–1546. doi: 10.1002/art.1780381104. [DOI] [PubMed] [Google Scholar]
  • 6.Anonymous. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update: American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. 2000; 43: 1905–1915. [DOI] [PubMed]
  • 7.Pendleton A, Arden N, Dougados M, et al. EULAR recommendations for the management of osteoarthritis: report of task force standing committee for international clinical studies including therapeutic trials (ESCISIT) Ann Rheum Dis. 2000;59:936–944. doi: 10.1136/ard.59.12.936. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med. 1998;105:31S–38S. doi: 10.1016/S0002-9343(98)00072-2. [DOI] [PubMed] [Google Scholar]
  • 9.Griffin MR. Epidemiology of nonsteroidal anti-inflammatory drug associated gastrointestinal injury. Am J Med. 1998;104:23S–29S. doi: 10.1016/S0002-9343(97)00207-6. [DOI] [PubMed] [Google Scholar]
  • 10.Wright JM. Double-edged sword of COX-2 selective NSAIDs. CMAJ. 2002;167:1131–1137. [PMC free article] [PubMed] [Google Scholar]
  • 11.Singh GB, Atal CK. Pharmacology of an extract of salai guggal ex-Boswellia serrata, a new non-steroidal anti-inflammatory agent. Agents Actions. 1986;18:407–441. doi: 10.1007/BF01965005. [DOI] [PubMed] [Google Scholar]
  • 12.Ethan B, Heather B, Theresa DH, Ivo F, Sadaf H, Jens H, David S, Catherine U. Boswellia. An evidence-based systematic review by the natural standard research collaboration. J Herbal Pharmacother. 2004;4:63–83. [PubMed] [Google Scholar]
  • 13.Safayhi H, Mack T, Sabieraj J, et al. Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther. 1992;26:1143–1146. [PubMed] [Google Scholar]
  • 14.Sailer ER, Subramanian LR, Rall B, et al. Acetyl-11-keto-β-boswellic acid (AKBA): structure requirements or binding and 5-lipoxygenase inhibitory activity. Br J Pharmacol. 1996;117:615–618. doi: 10.1111/j.1476-5381.1996.tb15235.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Kimmatkar N, Thawani V, Hingorani L, et al. Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee: a randomized double blind placebo controlled trial. Phytomedicine. 2003;10:3–7. doi: 10.1078/094471103321648593. [DOI] [PubMed] [Google Scholar]
  • 16.Perera PK, Perera M, Kumarasinghe N. Effect of Sri Lankan traditional medicine and Ayurveda on Sandhigata Vata (osteoarthritis of knee joint) Ayu. 2014;35:411–415. doi: 10.4103/0974-8520.159007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Shah MR, Mehta CS, Shukla VD, et al. A Clinical study of Matra Vasti and an ayurvedic indigenous compound drug in the management of Sandhigatavata (Osteoarthritis) Ayu. 2010;31:210–217. doi: 10.4103/0974-8520.72399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Gupta PK, Samarakoon SM, Chandola HM, et al. Clinical evaluation of Boswellia serrata (Shallaki) resin in the management of Sandhivata (osteoarthritis) Ayu. 2011;32:478–482. doi: 10.4103/0974-8520.96119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Roy S, Khanna S, Shah H, et al. Human genome screen to identify the genetic basis of the anti-inflammatory effects of Boswellia in microvascular endothelial cells. DNA Cell Biol. 2005;24:244–255. doi: 10.1089/dna.2005.24.244. [DOI] [PubMed] [Google Scholar]
  • 20.Syrovets T, Buchele B, Krauss C, et al. Acetyl-boswellic acids inhibit lipopolysaccharide mediated TNF-alpha induction in monocytes by direct interaction with IkappaB kinases. J Immunol. 2005;174:498–506. doi: 10.4049/jimmunol.174.1.498. [DOI] [PubMed] [Google Scholar]
  • 21.Roy S, Khanna S, Krishnaraju AV, et al. Regulation of vascular responses to inflammation: inducible matrix metalloproteinase-3 expression in human microvascular endothelial cells is sensitive to anti-inflammatory Boswellia. Antioxid Redox Signal. 2006;3:653–660. doi: 10.1089/ars.2006.8.653. [DOI] [PubMed] [Google Scholar]
  • 22.Sengupta K, Golakoti T, Marasetti A, et al. 30% 3-O-acetyl-11-keto-β-boswellic acid inhibits TNFα production and blocks MAPK/NFκB activation in lipopolysaccharide induced THP-1 human monocytes. J Food Lipids. 2009;16:325–344. doi: 10.1111/j.1745-4522.2009.01150.x. [DOI] [Google Scholar]
  • 23.Krishnaraju AV, Sundararaju D, Vamsikrishna U, et al. Safety and toxicological evaluation of Aflapin: a novel Boswellia-derived anti-inflammatory product. Toxicol Mech Methods. 2010;20:556–563. doi: 10.3109/15376516.2010.497978. [DOI] [PubMed] [Google Scholar]
  • 24.Sengupta K, Krishnaraju AV, Vishal AA, et al. Comparative efficacy and tolerability of 5-Loxin® and Aflapin® against osteoarthritis of the knee: a double blind, randomized, placebo controlled clinical study. Int J Med Sci. 2010;7:366–377. doi: 10.7150/ijms.7.366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Lalithakumari K, Krishnaraju AV, Sengupta K, et al. Safety and toxicological evaluation of a novel, standardized 3-O-acetyl-11-keto-β-boswellic acid (AKBA)-enriched Boswellia serrata extract (5-Loxin) Toxicol Mech Methods. 2006;16:199–226. doi: 10.1080/15376520600620232. [DOI] [PubMed] [Google Scholar]
  • 26.Sengupta K, Krishnaraju AV, Satish AR, et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. Arthritis Res Ther. 2008;10:R85. doi: 10.1186/ar2461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Gayathri B, Manjula N, Vinaykumar KS, et al. Pure compound from Boswellia serrata extract exhibits anti-inflammatory property in human PBMCs and mouse macrophages through inhibition of TNFα, IL-1β, NO and MAP kinases. Int Immunopharmacol. 2007;7:473–482. doi: 10.1016/j.intimp.2006.12.003. [DOI] [PubMed] [Google Scholar]
  • 28.Liu X, Machado GC, Eyles JP, Ravi V, Hunter DJ. Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis. Br J Sports Med. 2018;52:167–175. doi: 10.1136/bjsports-2016-097333. [DOI] [PubMed] [Google Scholar]
  • 29.Cameron M, Chrubasik S. Oral herbal therapies for treating osteoarthritis. Cochrane Database Syst Rev. 2014;22:CD002947. doi: 10.1002/14651858.CD002947.pub2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA group Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. BMJ. 2009;339:b2535. doi: 10.1136/bmj.b2535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Deeks JJ, Higgins JP, Altman DG. Chapter 16: special topics in statistics. In: Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions. UK: The Cochrane Collaboration; 2011. [Google Scholar]
  • 32.Deeks JJ, Higgins JP, Altman DG. Chapter 8: assessing risk of bias in included studies. In: Higgins JP Green S, editors. Cochrane handbook or systematic reviews of interventions version 5.1.0. UK: The Cochrane Collaboration; 2011. [Google Scholar]
  • 33.Vishal AA, Mishra A, Raychaudhuri SP. A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of aflapin in subjects with osteoarthritis of knee. Int J Med Sci. 2011;8:615–622. doi: 10.7150/ijms.8.615. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Haroyan A, Mukuchyan V, Mkrtchyan N, et al. Efficacy and safety of curcumin and its combination with boswellic acid in osteoarthritis: a comparative, randomized, double-blind, placebo-controlled study. BMC Complement Altern Med. 2018;18:7. doi: 10.1186/s12906-017-2062-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Karimifar M, Soltani R, Hajhashemi V, et al. Evaluation of the effect of Elaeagnus angustifolia alone and combined with Boswellia thurifera compared with ibuprofen in patients with knee osteoarthritis: a randomized double-blind controlled clinical trial. Clin Rheumatol. 2017;36:1849–1853. doi: 10.1007/s10067-017-3603-z. [DOI] [PubMed] [Google Scholar]
  • 36.Notarnicola A, Maccagnano G, Moretti L, et al. Methylsulfonylmethane and boswellic acids versus glucosamine sulfate in the treatment of knee arthritis: randomized trial. Int J Immunopathol Pharmacol. 2016;29:140–146. doi: 10.1177/0394632015622215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Notarnicola A, Tafuri S, Fusaro L, et al. The “MESACA” study: methylsulfonylmethane and boswellic acids in the treatment of gonarthrosis. Adv Ther. 2011;28:894–906. doi: 10.1007/s12325-011-0068-3. [DOI] [PubMed] [Google Scholar]
  • 38.Chopra A, Lavin P, Patwardhan B, Chitre D. A 32-week randomized, placebo-controlled clinical evaluation of RA-11, an Ayurvedic drug, on osteoarthritis of the knees. J Clin Rheumatol. 2004;10(5):236–245. doi: 10.1097/01.rhu.0000138087.47382.6d. [DOI] [PubMed] [Google Scholar]
  • 39.Chopra A, Saluja M, Tillu G, Sarmukkaddam S, Venugopalan A, Narsimulu G, Handa R, Sumantran V, Raut A, Bichile L, Joshi K, Patwardhan B. Ayurvedic medicine offers a good alternative to glucosamine and celecoxib in the treatment of symptomatic knee osteoarthritis: a randomized, double-blind, controlled equivalence drug trial. Rheumatology (Oxford) 2013;52(8):1408–1417. doi: 10.1093/rheumatology/kes414. [DOI] [PubMed] [Google Scholar]
  • 40.Belcaro G, Dugall M, Luzzi R, Ledda A, Pellegrini L, Hu S, Ippolito E. Management of osteoarthritis (OA) with the pharma-standard supplement FlexiQule (Boswellia): a 12-week registry. Minerva Gastroenterol Dietol. 2015;22 [Epub ahead of print]. [PubMed]
  • 41.Bolognesi G, Belcaro G, Feragalli B, Cornelli U, Cotellese R, Hu S, Dugall M. Movardol® (N-acetylglucosamine, Boswellia serrata, ginger) supplementation in the management of knee osteoarthritis: preliminary results from a 6-month registry study. Eur Rev Med Pharmacol Sci. 2016;20(24):5198–5204. [PubMed] [Google Scholar]
  • 42.Badria FA, et al. Boswellia–Curcumin Preparation for Treating Knee Osteoarthritis: A Clinical Evaluation. Alter and Comple Therap. 2002;12:341–348. doi: 10.1089/107628002761574635. [DOI] [Google Scholar]
  • 43.Loke Y, Price D, Herxheimer A. Chapter 14: adverse effects. In: JPT H, Green S, editors. Cochrane handbook for systematic reviews of interventions. Chapter 14. Chichester: Wiley; 2011. [Google Scholar]
  • 44.Ioannidis JP, Evans SJ, Gøtzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141:781–788. doi: 10.7326/0003-4819-141-10-200411160-00009. [DOI] [PubMed] [Google Scholar]
  • 45.Deeks JJ, Higgins JP, Altman DG. Chapter 9: Analyzing data and undertaking meta-analyses. In: Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions. UK: The Cochrane Collaboration; 2011. [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Additional file 1. (61.9KB, tif)
Additional file 2. (61.6KB, tif)
Additional file 3. (55.9KB, tif)
Additional file 4. (59.4KB, tif)
Additional file 5. (56.9KB, tif)
Additional file 6. (60.6KB, tif)
Additional file 7. (59.2KB, tif)
Additional file 8. (56.9KB, tif)
Additional file 9. (60.1KB, tif)
Additional file 10. (59.5KB, tif)
Additional file 11. (57.6KB, tif)
Additional file 12. (57.3KB, tif)

Data Availability Statement

All data generated or analyzed during this study are included in this published article and its supplementary information files.

Articles from BMC Complementary Medicine and Therapies are provided here courtesy of BMC

RESOURCES